CBDA and CBC — lesser-known cannabinoids: what they are and their uses (table)
CBDA and CBC — what they are, how they work, and what they help with. An understandable guide from u Bucha.
Most discussions about cannabinoids begin and end with CBD and THC. Meanwhile, the cannabis plant produces over 100 different cannabinoids — and some of them exhibit interesting biological properties independent of CBD. CBDA and CBC are two of the more promising 'overlooked' cannabinoids that are starting to appear in scientific research and on full-spectrum product labels. This article explains what they are, how they differ from CBD, and what science says about their potential effects — without exaggeration and without leaving gaps in knowledge.
KEY INFORMATION
• CBDA is the acidic precursor form of CBD — present in fresh, unheated cannabis; it transforms into CBD upon heating.
• CBDA shows a stronger affinity for 5-HT1A receptors than CBD, which may translate into a more pronounced anti-nausea effect (Rock et al., British Journal of Pharmacology, 2020).
• CBC (cannabichromene) is the third most concentrated cannabinoid in many cannabis strains — it primarily works by inhibiting the reuptake of anandamide.
• Neither CBDA nor CBC are psychoactive — neither binds significantly to the CB1 receptor.
• Entourage effect: both compounds may work synergistically with CBD — many full-spectrum products naturally contain them.
CBDA — the acidic form of CBD and its own properties
CBDA (cannabidiolic acid) is the natural precursor to CBD in the cannabis plant. The living plant does not directly produce CBD — it synthesizes CBDA from CBGA (cannabigerolic acid) as a parent compound. Only heating — through drying, vaporization, or baking — triggers decarboxylation and removes the carboxyl group, transforming CBDA into CBD (Rock et al., British Journal of Pharmacology, 2020).
For a long time, CBDA was treated merely as an inactive 'raw material' for CBD. Recent studies are changing this perception. Rock and colleagues demonstrated in 2020 that CBDA shows affinity for 5-HT1A serotonin receptors — and surprisingly, it is higher than that of CBD. The 5-HT1A receptors are crucial in regulating nausea, vomiting, and anxiety. This could explain why fresh cannabis juice (rich in CBDA) has traditionally been used for stomach issues.
Animal studies have shown that CBDA may be more effective than CBD in preventing chemotherapy-induced nausea — at lower doses and with a more pronounced effect. This is a promising observation, but it requires confirmation in clinical studies on humans, which are currently lacking. One should not conclude that CBDA 'cures' nausea — we have preclinical results, not clinical ones.
CBC — the third cannabinoid in line
CBC (cannabichromene) is the third most concentrated cannabinoid in many cannabis strains after CBD and THC. Its concentration in typical CBD flower ranges from 0.1% to over 1% dry weight. Like CBDA, CBC has been overlooked in research for years in favor of CBD and THC. However, newer studies show that it has its own distinct mechanisms of action.
The key mechanism of CBC is the inhibition of anandamide reuptake — an endogenous cannabinoid produced by the body, referred to as the 'bliss molecule' (ananda in Sanskrit = bliss). Anandamide naturally binds to CB1 and CB2 receptors as well as vanilloid receptors TRPV1. CBC blocks the transporter responsible for removing anandamide from the synapse, increasing its concentration and prolonging its effects (Izzo et al., British Journal of Pharmacology, 2009).
The mechanism of anandamide reuptake inhibition by CBC is analogous to the action mechanism of some antidepressant medications (selective serotonin reuptake inhibitors — SSRIs). CBC does the same, but for the endocannabinoid system instead of the serotonin system. This is an interesting pharmacological analogy, although the strength of the effect and clinical implications remain to be explored. It is worth keeping an eye on the scientific literature in this area.
Comparison table: CBDA vs CBC vs CBD
The table below compares the key features of CBDA and CBC against CBD. The data reflects the current state of scientific knowledge — for CBDA and CBC, most comes from preclinical studies.
| Feature | CBDA | CBC | CBD (for comparison) |
|---|---|---|---|
| Full name | Cannabidiolic acid | Cannabichromene | Cannabidiol |
| Precursor | CBGA → CBDA → CBD (after decarboxylation) | CBGA → CBCA → CBC (after decarboxylation) | Derived from CBDA |
| Psychoactivity | None | None | None |
| Main receptors | 5-HT1A (serotonin) | TRPA1, TRPV1, inhibition of AEA | 5-HT1A, TRPV1, CB1/CB2 (weak) |
| Potential effects | Antiemetic, anxiolytic | Anti-inflammatory, neuroprotection, pain | Anxiolytic, anti-inflammatory, pain |
| Strength of evidence | Preclinical + early clinical | Mainly preclinical | Clinical (epilepsy, anxiety) |
| Thermal stability | Low — converts to CBD upon heating | Moderate | High |
| Where to find? | Fresh hemp, raw full-spectrum oils | Full-spectrum products, high CBC flower | CBD oils, capsules, flower |
Stability of CBDA and CBC — degradation and storage
CBDA is thermally unstable — this is a characteristic that distinguishes it from CBD and CBC. Temperatures above 100°C initiate decarboxylation and the conversion of CBDA to CBD. This means that any hemp product subjected to heating (vaporization, cooking, high-temperature extraction) contains little to no CBDA. To preserve CBDA, one should choose products made using low-temperature extraction methods (subcritical CO₂ extraction, cold alcohol extraction) and stored without exposure to heat.
CBC is more thermally stable than CBDA — it withstands typical drying temperatures of the raw material and moderate extraction temperatures. In vaporized hemp flower, CBC is present at temperatures below 200°C. Above this threshold, its gradual degradation begins. This means that flower vaporized in the range of 170-190°C retains both terpenes and CBC, while flower burned at high combustion temperatures loses them completely.
UV light is another factor that degrades both compounds. Light-proof packaging (amber or dark green glass, opaque plastics) significantly extends the shelf life of the cannabinoid profile — including CBDA and CBC. Products sold in transparent bottles exposed to store lighting may have significantly lower concentrations of these sensitive cannabinoids than declared in the COA prepared immediately after production.
How to obtain CBDA and CBC from hemp products?
CBDA is mainly present in raw, unheated hemp products. Fresh juice from the leaves and flowers of hemp is the richest natural source of CBDA. CBD oils produced through CO₂ or alcohol extraction from unheated material retain some CBDA — check the label or COA to see if CBDA is listed as an ingredient.
Most commercial CBD oils are made from dried, decarboxylated plant material — CBDA has already been converted to CBD. Products with 'raw' or 'unprocessed' in the name suggest the preservation of CBDA, but always verify this through a COA with a cannabinoid profile. A true 'raw' product should have a detectable amount of CBDA listed in the laboratory report.
You can find CBC naturally in full-spectrum products — oils and flowers from hemp strains rich in CBC. The CBC content is usually listed in the COA with the full cannabinoid profile. Products isolating pure CBD do not contain CBC. It's worth noting that CBD flower vaporized at low temperatures (170-185°C) retains more CBC than when smoked, as CBC is more thermally stable than CBDA.
We are observing a growing interest in 'full spectrum' and 'broad spectrum' products among customers who have tried CBD isolate without satisfactory results. A natural explanation may be the entourage effect — the presence of CBDA, CBC, CBG, terpenes, and other compounds may account for the difference in sensations between isolate and full-spectrum oil, even with identical CBD content. This is not certain scientific knowledge — but a hypothesis with increasing support in the literature.
Frequently Asked Questions
What is the difference between CBDA and CBD?
CBDA (cannabidiolic acid) is the acidic precursor form of CBD naturally present in the fresh, unheated hemp plant. Upon heating, CBDA undergoes decarboxylation and converts into CBD. CBDA has its own biological activity — it shows a stronger affinity for serotonin receptors 5-HT1A than CBD, which may translate into a more pronounced antiemetic and anxiolytic effect (Rock et al., British Journal of Pharmacology, 2020).
What can CBC help with?
CBC shows several potential actions in preclinical studies: inhibition of anandamide reuptake (increased endogenous cannabinoid), anti-inflammatory action through CB receptor-independent pathways, neuroprotective potential (stimulation of neurogenesis in vitro), and synergistic analgesic action with CBD (Izzo et al., British Journal of Pharmacology, 2009). There is a lack of randomized clinical studies in humans.
Are CBDA and CBC psychoactive?
No — neither CBDA nor CBC are psychoactive. Neither of these compounds significantly binds to the CB1 receptor responsible for the intoxicating effect of THC. CBDA mainly acts through serotonin receptors, while CBC acts through TRPA1/TRPV1 and anandamide. Both can be used without concern for a psychoactive effect.
Where is CBC naturally found in hemp?
CBC is the third most abundant cannabinoid in many hemp strains — after CBD and THC. Its concentration ranges from 0.1% to over 1% of dry weight. It is produced from CBCA (cannabichromene acid) through decarboxylation. Strains bred for high CBD content usually also contain measurable concentrations of CBC — check the COA of the product you are purchasing.
Does the entourage effect work with CBDA and CBC?
The entourage effect is the hypothesis that the full spectrum of cannabinoids and terpenes works synergistically better than isolated compounds. CBDA shows higher affinity for 5-HT1A than CBD — both may act complementarily on serotonin receptors. CBC increases anandamide levels, which may enhance the overall effect of full-spectrum hemp products. This is a promising hypothesis with growing preclinical support, but it requires further clinical research.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
